- Home
- PARR vs RARE Comparison
PARR vs RARE Comparison
Compare PARR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | RARE |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PARR | RARE |
|---|---|---|
| Price | $70.15 | $32.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $70.17 | $59.10 |
| AVG Volume (30 Days) | 943.9K | ★ 3.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | 7.31 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $2,443,066,000.00 | $673,000,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | $3.78 | $37.80 |
| P/E Ratio | $59.80 | ★ N/A |
| Revenue Growth | ★ 30.99 | 20.13 |
| 52 Week Low | $26.83 | $18.29 |
| 52 Week High | $70.39 | $39.89 |
Technical Indicators
Market Signals| Indicator | PARR | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 71.91 | 59.56 |
| Support Level | $55.45 | $31.82 |
| Resistance Level | N/A | $34.01 |
| Average True Range (ATR) | 2.77 | 1.70 |
| MACD | 1.76 | 0.10 |
| Stochastic Oscillator | 97.68 | 45.73 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.